文档介绍：复方甲氧那明联合孟鲁司特钠治疗咳嗽变异性哮喘的临床效果
[摘要]目的 探討复方甲氧那明联合孟鲁司特钠治疗咳嗽变异性哮喘(CVA)的临床效果。方法 选取2017年4月~2018年4月我院收治的68例CVA患者作为研究对象。按照随nts before treatment (P>). After treatment, the daytime cough score and nocturnal cough score in the study group were (±) and (±) points, respectively, which were lower than those in the control group for (±) and (±) points respectively, the differences were statistically significant (P<). The total incidence of adverse reactions in the study group was %, lower than % of the control group, the difference was statistically significant (P<). Conclusion Clinical effect of Compound Methoxymine combined with Montelukast Sodium in the treatment of CVA is remarkable. [Key words] Compound Methoxymine; Montelukast Sodium; Cough variant asthma; Effect; Effective rate
咳嗽变异性哮喘(cough variant asthma,CVA)属于临床常见的哮喘类型[1],气道高反应性即由于各种刺激作用下,导致气管呈高度敏感状态,常见为支气管哮喘。CVA临床症状主要为刺激性干咳,且咳嗽较剧烈,其重要特征为夜间咳嗽、凌晨咳嗽。且冷空气、感冒、灰尘、油烟等容易诱发咳嗽或加重咳嗽[2-3]。气道高反应性包括咳嗽变异性哮喘类型、老年人慢性支气管炎类型等[4]。气道高反应性疾病发作中,患者多表现为刺激性干咳症状、喘鸣症状、胸闷症状、呼吸困难症状等,对患者的身心健康、生活质量造成严重影响[5-6]。临床主要实施吸入性糖皮质激素治疗CVA,可起到抑制气道炎症作用,有效阻滞气道重塑,能在短时间内改善临床症状,但远期疗效则不理想,且十分容易复发[7-8]。本研究探讨复方甲氧那明联合孟鲁司特钠治疗CVA的临床效果,现报道如下。
1资料与方法
选取2017年4月~2018年4月我院收治的68例CVA患者作为研究对象,根据随机数字表法分为对照组和研究组,每组各34例。研究组中,男19例,女15例;年龄20~79岁,平均(±)岁;疾病类型:均为CVA。对照组中,男20例,女14例;年龄20~79岁,平均(±)岁